EUVIMEDEUVIMED entdecken
Crossref

Tepotinib (Tepmetko) for NSCLC

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1701f ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Rosacea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has granted regular approval to the oral kinase inhibitor tepotinib (Tepmetko – EMD Serono) for treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaHumansDermatologic AgentsAdministration, CutaneousAdministration, Topical

Stichwörter der Autor:innen

Tepmetkoadverse effectsdosagedrug interactionsefficacylactationlung cancerpregnancysafetytepotinib

Substanzen

Dermatologic Agents

Zitieren

APA

(2024). Tepotinib (Tepmetko) for NSCLC. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1701f

Vancouver

Tepotinib (Tepmetko) for NSCLC. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1701f

BibTeX
@article{euvimed2024,
  title = {Tepotinib (Tepmetko) for NSCLC},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1701f}
}
Kostenlos starten →